

## **DDEA Board of Directors Conflicts relating to collaboration with life-science industry**

According to the Code of Conduct relating to collaboration by the Danish Diabetes and Endocrine Academy (DDEA) and the DDEA Board of Directors (BoD) with the life-science industry, the BoD members have disclosed the following potential conflicts of interest by 1 January 2025.

### **Troels Krarup Hansen (Chair)**

None

### **Julie Abildgaard**

None

### **Lise Wogensen Bach**

None

### **Jakob Dal**

None

### **Marie-Louise Hartoft-Nielsen**

Employee of the Novo Nordisk Foundation and thus “receives payment from a life-science partner”.

### **Anders Hoff**

Employee of the Danish Association of the Pharmaceutical Industry and thus “receives payment from a life-science partner”

### **Martin Blomberg Jensen**

- CEO and founder of the Region Hovedstaden spin out: XY therapeutics Aps
- FAES Pharma: advisory board 2024
- Studies in infertility sponsored in part by XY therapeutics.
- Studies in infertility sponsored in part by Repronovo
- Speaker (fee) from Gedeon Richter, Merck, Amgen, Novo AS